SCHEMBL4516346

SCHEMBL4516346

CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)c1nccc(-c2ccc(N)cc2)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.36
IKBKB O14920 2/20 0.36
PAX8 Q06710 1/20 0.36
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
KDM4E B2RXH2 2/20 0.35
PRNP P04156 1/20 0.35
POLB P06746 1/20 0.35
GAA P10253 1/20 0.35
LTB4R Q15722 1/20 0.35
MAP4K4 O95819 1/20 0.35
CAMK2D Q13557 1/20 0.34
AAK1 Q2M2I8 5/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
KMO O15229 1/20 0.34
DYRK1A Q13627 1/20 0.34
PDPK1 O15530 1/20 0.34
DUSP10 Q9Y6W6 1/20 0.34
GMNN O75496 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31396449 0.83 PIK3CA (0.45) MEN1KMT2AGAANPC1RAB9A
SCHEMBL12134343 0.76 SYK (0.53) SYKLTB4RMAP4K4AAK1DYRK1A
SCHEMBL4532204 0.76 CIT (0.42) PAX8DUSP10CYP3A4PKM
SCHEMBL1881782 0.76 SSTR4 (0.37) SYKPAX8MEN1KMT2AAAK1
SCHEMBL28481850 0.75 AAK1 (0.49) AAK1CYP3A4
SCHEMBL24529116 0.75 SSTR4 (0.41) SYKPAX8AAK1NPC1RAB9A
SCHEMBL16806443 0.75 ATR (0.41) SYKPAX8KMT2APOLBAAK1
SCHEMBL30226544 0.75 ATR (0.41) SYKPAX8KMT2APOLBAAK1
SCHEMBL4529959 0.74 PAX8 (0.37) PAX8POLBDUSP10ALDH1A1MAPT
SCHEMBL4519488 0.74 MAP4K4 (0.36) SYKPAX8MEN1KMT2AMAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12208098-B2 4-carbonylamino-4-phenylpyrimidine compound or pharmaceutically acceptable salt thereof GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2025-01-28 US disclosed
US-8211919-B2 Amide derivatives as rock inhibitors ASTELLAS PHARMA INC. (JP) 2012-07-03 US disclosed
US-20090105231-A1 AMIDE DERIVATIVES AS ROCK INHIBITORS ASTELLAS PHARMA INC. (JP) 2009-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12208098-B2 4-carbonylamino-4-phenylpyrimidine compound or pharmaceutically acceptable salt thereof SLC5A1, SLC10A1, DPP4 SYK 2668/4885IKBKB 614/4885PAX8 3322/4885
US-20090105231-A1 AMIDE DERIVATIVES AS ROCK INHIBITORS ROCK1, ROCK2, RHOA SYK 891/4885IKBKB 489/4885PAX8 3961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.